- Home
- ABSI vs MBX Comparison
ABSI vs MBX Comparison
Compare ABSI & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- MBX
- Stock Information
- Founded
- ABSI 2011
- MBX 2018
- Country
- ABSI United States
- MBX United States
- Employees
- ABSI N/A
- MBX N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- MBX
- Sector
- ABSI Health Care
- MBX
- Exchange
- ABSI Nasdaq
- MBX NYSE
- Market Cap
- ABSI 353.8M
- MBX 300.5M
- IPO Year
- ABSI 2021
- MBX 2024
- Fundamental
- Price
- ABSI $2.75
- MBX $11.11
- Analyst Decision
- ABSI Strong Buy
- MBX Strong Buy
- Analyst Count
- ABSI 5
- MBX 5
- Target Price
- ABSI $8.40
- MBX $37.40
- AVG Volume (30 Days)
- ABSI 2.5M
- MBX 333.6K
- Earning Date
- ABSI 05-13-2025
- MBX 05-16-2025
- Dividend Yield
- ABSI N/A
- MBX N/A
- EPS Growth
- ABSI N/A
- MBX N/A
- EPS
- ABSI N/A
- MBX N/A
- Revenue
- ABSI $4,534,000.00
- MBX N/A
- Revenue This Year
- ABSI $158.58
- MBX N/A
- Revenue Next Year
- ABSI $93.12
- MBX N/A
- P/E Ratio
- ABSI N/A
- MBX N/A
- Revenue Growth
- ABSI N/A
- MBX N/A
- 52 Week Low
- ABSI $2.01
- MBX $4.81
- 52 Week High
- ABSI $6.33
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- ABSI 42.92
- MBX N/A
- Support Level
- ABSI $2.85
- MBX N/A
- Resistance Level
- ABSI $2.94
- MBX N/A
- Average True Range (ATR)
- ABSI 0.19
- MBX 0.00
- MACD
- ABSI -0.03
- MBX 0.00
- Stochastic Oscillator
- ABSI 14.13
- MBX 0.00
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.